Unlocking the Potential of DNAJC3-DT: A Potential Drug Target and Biomarker

Target Name: DNAJC3-DT

NCBI ID: G100289274

DNAJC3-DT

Other Name(s): DNAJC3 divergent transcript | DNAJC3-AS1

Unlocking the Potential of DNAJC3-DT: A Potential Drug Target and Biomarker

DNAJC3-DT, also known as DNAJC3, is a protein that is expressed in various tissues of the body, including muscle, heart, and brain. Its primary function is to regulate the structure and function of the myosin filaments, which are essential for muscle contraction and relaxation. DNAJC3 has been identified as a potential drug target and biomarker due to its unique structure and function. In this article, we will explore the potential of DNAJC3 as a drug target and biomarker, and discuss its clinical implications.

Potential Drug Target

DNAJC3 is a protein that can interact with several drug molecules, including small molecules, peptides, and proteins. Its unique structure and function make it an attractive drug target. One of the primary targets of DNAJC3 is the regulation of myosin filament dynamics. Myosin filaments are composed of the protein Myosin and the protein T-tubulin. The regulation of their dynamics is critical for muscle contraction and relaxation.

DNAJC3 has been shown to play a role in the regulation of myosin filament dynamics. It interacts with the protein Myosin regulatory protein 1 (Myosin-RP1), which is a key regulator of myosin filament dynamics. By interacting with Myosin-RP1, DNAJC3 can regulate the distribution of Myosin in the cytoplasm and influence the dynamics of myosin filament formation and disassembly.

In addition to its role in myosin filament regulation, DNAJC3 has also been shown to play a role in the regulation of mitochondrial dynamics. It interacts with the protein Mitofusin, which is involved in the regulation of mitochondrial fusion and fusion-proximal events. This interaction between DNAJC3 and Mitofusin suggests that DNAJC3 may also be a potential drug target for diseases related to mitochondrial dysfunction, such as heart disease and neurodegenerative diseases.

Potential Biomarker

DNAJC3 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive biomarker due to its ability to be used in non-invasive or minimally invasive procedures.

DNAJC3 has been shown to be expressed in various tissues of the body, including cancer cells, neurodegenerative diseases, and autoimmune disorders. Its expression has also been associated with the development of certain diseases. For example, DNAJC3 has been shown to be expressed in pancreatic cancer cells, and its expression has been associated with poor prognosis in pancreatic cancer patients. Similarly, DNAJC3 has been shown to be expressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and its expression has been associated with the severity of these diseases.

In addition to its expression in disease tissues, DNAJC3 has also been shown to be expressed in normal tissues of the body, including muscle and heart cells. This suggests that DNAJC3 may be a potential biomarker for diseases that affect these tissues, such as muscle or heart disease.

Clinical Implications

The potential of DNAJC3 as a drug target and biomarker makes it an attractive target for research into a variety of diseases.

In oncology, DNAJC3 has been shown to be a potential drug target for cancer. Its regulation of myosin filament dynamics has been shown to be critical for the development and progression of cancer. By inhibiting the

Protein Name: DNAJC3 Divergent Transcript

The "DNAJC3-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJC3-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets